Analisi costo/efficacia di sevelamer nel trattamento dell’iperfosforemia del paziente in dialisi

by Mario Eandi, Nicola Giotta, Gaia Santagostino Barbone
Published 2004-12-01

First drug utilization data related to an anticholinergic agent recently marketed in Italy

by Carlo Lucioni, S. Mazzi, C. Cerra, S. Lottaroli
Published 2006-09-01

Il costo medio per tipologia di prestazione nei centri trasfusionali

by Silvia Martina, Dante Cornago, Livio Garattini, Emanuela Castelnuovo
Published 2003-03-01

Dabigatran in the prevention of venous thromboembolism after major orthopedic surgery

by Orietta Zaniolo
Published 2009-09-01

Taxane therapy in the adjuvant treatment of breast cancer in Italy: economic evaluation

by Simona Ravera, Lorenzo G. Mantovani
Published 2006-03-01

The pharmaceutical expenditure in Italy in 2009: toward regional federalism

by Mario Eandi
Published 2009-01-01

Telithromycin (Ketek®)in lower respiratory tract infections: economic aspects

by Carlo Lazzaro
Published 2006-09-01

Perceval Sutureless valves in isolated and concomitant AVR procedures: an economic model shows overall decrease of costs for isolated or combined operations

by Lorenzo Pradelli, Orietta Zaniolo
Published 2012-12-01

Essential to increase the use of generics in Europe to maintain comprehensive health care?

by Brian Godman, Marion Bennie, Christoph Baumgärtel, Ljiljana Sović-Brkičić, Thomas Burkhardt, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Vanda Markovic-Pekovic, Andrew Martin, Catherine Sermet, Peter Skiold, Menno van Woerkom, Luka Voncina, Lars L. Gustafsson
Published 2012-12-01

[Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in Italy]

by Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Giulia Vestri, Luigi Giuliani, Diego Centonze, Pier Luigi Canonico
Published 2016-07-01

Budget impact analysis of use of aliskiren in hypertension on the Italian Health Care System

by Orietta Zaniolo, Lorenzo Pradelli
Published 2009-03-01

Prevenzione e terapia precoce del diabete mellito di tipo II: aspetti farmacoeconomici

by Lorenzo Pradelli
Published 2005-09-01

Valle d’Aosta

by Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
Published 2012-11-01

GOLD guidelines adherence impact on the NHS budget

by Alessandro Guasconi, Claudio Ripellino, Franca Heiman
Published 2014-03-01

Olanzapine versus typical neuroleptics for schizophrenia: evaluation of social and economic costs

by Giorgio Mariani, Luca Guidi, Angelomarco Barioglio
Published 2006-09-01

Bayesian statistic methods and theri application in probabilistic simulation models

by Sergio Iannazzo
Published 2007-03-01

Veneto

by Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
Published 2012-11-01

Role of pharmacoeconomics in developing countries

by Amani Mori, Paul Gavaza, Bjarne Robberstad
Published 2013-01-01

[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]

by Sergio Iannazzo, Edoardo Mannucci, Lorenzo Mantovani
Published 2016-03-01

Mental health parity legislation: Anticipating costs and benefits

by Arlene Smaldone, Mary Cullen-Drill
Published 2012-07-01